SEQUENCE LISTING

| <110> HAGIWARA Yoshihide | |
|---|----|
| <120> Method of Optaining Human Monoclonal Antibodies Having Cancer Cell Proliferation-Inhibiting Activity | |
| <130> K-27Hagi | |
| <150> JP2002/335281 <151> 2002-11-19 | |
| <160> 4 | |
| <210> 1 <211> 24 <212> DNA <213> Artificial Sequence | |
| <220> <223>Synthesized Referring to the Sequence Of Human Vimentin | |
| <400> 1 tagcggccgc attctgaatc tcat | 24 |
| <210> 2 <211> 26 <212> DNA <213> Artificial Sequence | |
| <220> <223> Synthesized Referring to the Sequence Of Human Vimentin | |
| <400> 2 gcggccgcat cctgcaggcg gccaat | 26 |
| <210> 3 <211> 25 <212> DNA <213> Artificial Sequence | |
| <220> <223> Synthesized Referring to the Sequence Of Human Vimentin | |
| <400> 3 tagcggccgc catattctga atctc | 25 |

```
<210> 4
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized Referring to the Sequence Of Human Vimentin
<400> 4
ccagaattcc aggctcagat tcag
                                                                        24
<210> 5
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized Referring to the Sequence Of Human Vimentin
<400> 5
                                                                        24
cgggaattcg aatggtacaa atcc
<210> 6
<211> 127
<212> PRT
<213> human
<220>
<223>
<400> 6
Gln Ala Gln Ile Gln Glu Gln His Val Gln Ile Asp Val Asp Val Ser
Lys Pro Asp Leu Thr Ala Ala Leu Arg Asp Val Arg Gln Gln Tyr Glu
                                  25
Ser Val Ala Ala Lys Asn Leu Gln Glu Ala Glu Glu Trp Tyr Lys Ser
Lys Phe Ala Asp Leu Ser Glu Ala Ala Asn Arg Asn Asp Ala Leu
                         55
Arg Gln Ala Lys Gln Glu Ser Thr Glu Tyr Arg Arg Gln Val Gln Ser
                                          75
Leu Thr Cys Glu Val Asp Ala Leu Lys Gly Thr Asn Glu Ser Leu Glu
                 85
                                      90
Arg Gln Met Arg Glu Met Glu Glu Asn Phe Ala Val Glu Ala Ala Asn
            100
                                 105
                                                     110
```

Tyr Gln Asp Thr lie Gly Arg Leu Gln Asp Glu lie Gln Asn Met 115 120 125